Home > Insider Trading > Filing (0001615774-17-005170)

Filing Details

Accession Number:: 0001615774-17-005170
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-09-18 21:13:19
Reporting Period:: 2017-09-18

Accepted Time:: 2017-09-18 21:13:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1641640	Nabriva Therapeutics Plc	NBRV	()	1231

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1618789	Vivo Capital Viii, Llc	505 Hamilton Avenue, Suite 207 Palo Alto CA 94301		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-09-18	46,245	$9.46	3,579,861	No	4	P	Indirect	by Vivo Hong Kong VIII, Co., Limited
Common Stock	Acquisiton	2017-09-18	6,386	$9.46	494,329	No	4	P	Indirect	Vivo Hong Kong Surplus VIII, Co., Limited

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	by Vivo Hong Kong VIII, Co., Limited
No	4	P	Indirect	Vivo Hong Kong Surplus VIII, Co., Limited

Footnotes

These shares are owned directly by Vivo Hong Kong VIII, Co., Limited and Vivo Hong Kong Surplus VIII, Co., Limited, which are the record owners (together, the "Record Owners") of these shares. The Record Owners are wholly owned subsidiaries of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., respectively (together, the "Parents").
Vivo Capital VIII, LLC is the general partner of the Parents and disclaims beneficial ownership over these shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The voting members of Vivo Capital VIII, LLC are Dr. Frank Kung, Dr. Albert Cha, Dr. Edgar Engleman, Dr. Chen Yu, and Mr. Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.60, inclusive. The reporting person undertakes to provide to Nabriva Therapeutics plc, any security holder of Nabriva Therapeutics plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.